Company Overview
Snapshot
Founded in November 2025, Immunovation TX operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of novel immunotherapy-based treatments for cancer.
Business overview
Immunovation TX is an Israeli biotech startup dedicated to developing advanced immunotherapy treatments for cancer. The company's core technology leverages the immune system to precisely target and eliminate tumor cells while preserving healthy tissue. Its R&D efforts are concentrated on proprietary therapeutic platforms and drug candidates designed to enhance the efficacy, safety, and durability of responses compared to existing oncology treatments. Immunovation TX aims to address significant unmet medical needs in oncology and improve patient outcomes through collaborations with clinical and academic partners, advancing its pipeline toward clinical validation and regulatory approval.
Company Intelligence Q&A
- What is Immunovation TX's primary focus in the biotechnology sector?
- Immunovation TX is an Israeli biotech startup focused on developing novel immunotherapy-based treatments for cancer. The company aims to leverage the immune system to selectively target and destroy tumor cells.
- What is the core technological approach of Immunovation TX?
- Immunovation TX's R&D is centered on proprietary therapeutic platforms and drug candidates designed to improve the efficacy, safety, and durability of response in oncology treatments compared to existing options.
- What stage of development is Immunovation TX currently in?
- Immunovation TX is currently in the Pre-Funding stage, with its products in the R&D phase, working towards clinical validation and regulatory approval.
- What markets or industries does Immunovation TX serve?
- Immunovation TX operates within the oncology market, aiming to address high unmet medical needs and improve patient outcomes through its immunotherapy solutions.
- When was Immunovation TX founded?
- Immunovation TX was founded in November 2025.